@article{ScholzCosgareaSuesskindetal.2018,
  author    = {Scholz, S. L. and Cosgarea, I. and S{\"u}ßkind, D. and Murali, R. and M{\"o}ller, I. and Reis, H. and Leonardelli, S. and Schilling, B. and Schimming, T. and Hadaschik, E. and Franklin, C. and Paschen, A. and Sucker, A. and Steuhl, K. P. and Schadendorf, D. and Westekemper, H. and Griewank, K. G.},
  title     = {NF1 mutations in conjunctival melanoma},
  series = {British Journal of Cancer},
  volume    = {118},
  journal   = {British Journal of Cancer},
  doi       = {10.1038/s41416-018-0046-5},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-233329},
  pages     = {1243-1247},
  year      = {2018},
  abstract  = {Background Conjunctival melanoma is a potentially deadly eye tumour. Despite effective local therapies, tumour recurrence and metastasis remain frequent. The genetics of conjunctival melanomas remain incompletely understood. Methods A large cohort of 63 conjunctival melanomas was screened for gene mutations known to be important in other melanoma subtypes by targeted next-generation sequencing. Mutation status was correlated with patient prognosis. Results Frequent mutations in genes activating the MAP kinase pathway were identified. NF1 mutations were most frequent (n = 21, 33\%). Recurrent activating mutations were also identified in BRAF (n = 16, 25\%) and RAS genes (n = 12, 19\%; 11 NRAS and 1 KRAS). Conclusions Similar to cutaneous melanomas, conjunctival melanomas can be grouped genetically into four groups: BRAF-mutated, RAS-mutated, NF1-mutated and triple wild-type melanomas. This genetic classification may be useful for assessment of therapeutic options for patients with metastatic conjunctival melanoma},
  language  = {en}
}